Martha Raluca Neagu Aristide

机构：AbbVie (United States)

发表论文 18 篇 · 总被引 84 次 · h-index 6

代表论文

• First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. (2024 · Journal of Clinical Oncology · 被引 21)
• Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma (2022 · Neuro-Oncology Advances · 被引 14)
• 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study (2024 · Annals of Oncology · 被引 12)
• Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 12)
• 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study (2024 · Annals of Oncology · 被引 9)
• 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors (2023 · Annals of Oncology · 被引 7)